This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hara, T. Articles by Miyamoto, M. Search for Related Content PubMed PubMed Citation Articles by Hara, T. Articles by Miyamoto, M.

Novel Mutations of Androgen Receptor

A Possible Mechanism of Bicalutamide Withdrawal Syndrome

Pharmaceutical Research Laboratories I [T. H., H. A., M. Y., M. K., M. M.] and Pharmaceutical Discovery Center [J. M., N. K.], Takeda Chemical Industries, Ltd., Osaka 532-8686, Japan

Most prostate cancers (PCs) become resistant to combined androgen blockade therapy with surgical or medical castration and antiandrogens after several years. Some of these refractory PCs regress after discontinuation of antiandrogen administration [antiandrogen withdrawal syndrome (AWS)]. Although the molecular mechanisms of the AWS are not fully understood because of the lack of suitable experimental models, one hypothesis of the mechanism is mutation of androgen receptor (AR). However, bicalutamide, which has become the most prevalent pure antiandrogen, does not work as an agonist for any mutant AR detected thus far in PC. To elucidate the mechanisms of the AWS, we established and characterized novel LNCaP cell sublines, LNCaP-cxDs, which were generated in vitro by culturing androgen-dependent LNCaP-FGC human PC cells in androgen-depleted medium with bicalutamide to mimic the combined androgen blockade therapy. LNCaP-FGC cells did not grow at first, but they started to grow after 6–13 weeks of culture. Bicalutamide stimulated LNCaP-cxD cell growth and increased prostate-specific antigen secretion from LNCaP-cxD cells both in vitro and in vivo. Sequencing of AR transcripts revealed that the AR in LNCaP-cxD cells harbors a novel mutation in codon 741, TGG (tryptophan) to TGT (cysteine; W741C), or in codon 741, TGG to TTG (leucine; W741L), in the ligand-binding domain. Transactivation assays showed that bicalutamide worked as an agonist for both W741C and W741L mutant ARs. Importantly, another antiandrogen, hydroxyflutamide, worked as an antagonist for these mutant ARs. In summary, we demonstrate for the first time that within only 6–13 weeks of in vitro exposure to bicalutamide, LNCaP-FGC cells, whose growth had initially been suppressed, came to use bicalutamide as an AR agonist via W741 AR mutation to survive. Our data strongly support the hypothesis that AR mutation is one possible mechanism of the AWS and suggest that flutamide might be effective as a second-line therapy for refractory PC previously treated with bicalutamide.

This article has been cited by other articles:

				O. A. O'Mahony, M. P. Steinkamp, M. A. Albertelli, M. Brogley, H. Rehman, and D. M. Robins Profiling Human Androgen Receptor Mutations Reveals Treatment Effects in a Mouse Model of Prostate Cancer Mol. Cancer Res., November 1, 2008; 6(11): 1691 - 1701. [Abstract] [Full Text] [PDF]

				H. Wang, D. Sun, P. Ji, J. Mohler, and L. Zhu An AR-Skp2 pathway for proliferation of androgen-dependent prostate-cancer cells J. Cell Sci., August 1, 2008; 121(15): 2578 - 2587. [Abstract] [Full Text] [PDF]

				S. M. Dehm and D. J. Tindall Androgen Receptor Structural and Functional Elements: Role and Regulation in Prostate Cancer Mol. Endocrinol., December 1, 2007; 21(12): 2855 - 2863. [Abstract] [Full Text] [PDF]

				C.-T. Wu, W.-C. Chen, S.-K. Liao, C.-L. Hsu, K.-D. Lee, and M.-F. Chen The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy Endocr. Relat. Cancer, September 1, 2007; 14(3): 633 - 643. [Abstract] [Full Text] [PDF]

				M. C. Hodgson, I. Astapova, A. N. Hollenberg, and S. P. Balk Activity of Androgen Receptor Antagonist Bicalutamide in Prostate Cancer Cells Is Independent of NCoR and SMRT Corepressors Cancer Res., September 1, 2007; 67(17): 8388 - 8395. [Abstract] [Full Text] [PDF]

				K. Iguchi, K. Ishii, T. Nakano, T. Otsuka, S. Usui, Y. Sugimura, and K. Hirano Isolation and Characterization of LNCaP Sublines Differing in Hormone Sensitivity J Androl, September 1, 2007; 28(5): 670 - 678. [Abstract] [Full Text] [PDF]

				S. Lu, A. Wang, S. Lu, and Z. Dong A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells Mol. Cancer Ther., July 1, 2007; 6(7): 2057 - 2064. [Abstract] [Full Text] [PDF]

				C. E. Bohl, Z. Wu, D. D. Miller, C. E. Bell, and J. T. Dalton Crystal Structure of the T877A Human Androgen Receptor Ligand-binding Domain Complexed to Cyproterone Acetate Provides Insight for Ligand-induced Conformational Changes and Structure-based Drug Design J. Biol. Chem., May 4, 2007; 282(18): 13648 - 13655. [Abstract] [Full Text] [PDF]

				S. Srinivasan, R. S. Ranga, R. Burikhanov, S.-S. Han, and D. Chendil Par-4-Dependent Apoptosis by the Dietary Compound Withaferin A in Prostate Cancer Cells Cancer Res., January 1, 2007; 67(1): 246 - 253. [Abstract] [Full Text] [PDF]

				Y. B. Wetherill, J. K. Hess-Wilson, C. E.S. Comstock, S. A. Shah, C. R. Buncher, L. Sallans, P. A. Limbach, S. Schwemberger, G. F. Babcock, and K. E. Knudsen Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer Mol. Cancer Ther., December 1, 2006; 5(12): 3181 - 3190. [Abstract] [Full Text] [PDF]

				H. Le, J. T. Arnold, K. K. McFann, and M. R. Blackman DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E952 - E960. [Abstract] [Full Text] [PDF]

				V. Georget, W. Bourguet, S. Lumbroso, S. Makni, C. Sultan, and J.-C. Nicolas Glutamic Acid 709 Substitutions Highlight the Importance of the Interaction between Androgen Receptor Helices H3 and H12 for Androgen and Antiandrogen Actions Mol. Endocrinol., April 1, 2006; 20(4): 724 - 734. [Abstract] [Full Text] [PDF]

				B. He, R. T. Gampe Jr., A. T. Hnat, J. L. Faggart, J. T. Minges, F. S. French, and E. M. Wilson Probing the Functional Link between Androgen Receptor Coactivator and Ligand-binding Sites in Prostate Cancer and Androgen Insensitivity J. Biol. Chem., March 10, 2006; 281(10): 6648 - 6663. [Abstract] [Full Text] [PDF]

				J. Duff and I. J. McEwan Mutation of Histidine 874 in the Androgen Receptor Ligand-Binding Domain Leads to Promiscuous Ligand Activation and Altered p160 Coactivator Interactions Mol. Endocrinol., December 1, 2005; 19(12): 2943 - 2954. [Abstract] [Full Text] [PDF]

				C. E. Bohl, D. D. Miller, J. Chen, C. E. Bell, and J. T. Dalton Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor J. Biol. Chem., November 11, 2005; 280(45): 37747 - 37754. [Abstract] [Full Text] [PDF]

				T. Yoshida, H. Kinoshita, T. Segawa, E. Nakamura, T. Inoue, Y. Shimizu, T. Kamoto, and O. Ogawa Antiandrogen Bicalutamide Promotes Tumor Growth in a Novel Androgen-Dependent Prostate Cancer Xenograft Model Derived from a Bicalutamide-Treated Patient Cancer Res., November 1, 2005; 65(21): 9611 - 9616. [Abstract] [Full Text] [PDF]

				R. Ilagan, L. J. Zhang, J. Pottratz, K. Le, S. Salas, M. Iyer, L. Wu, S. S. Gambhir, and M. Carey Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model Mol. Cancer Ther., November 1, 2005; 4(11): 1662 - 1669. [Abstract] [Full Text] [PDF]

				P. Farla, R. Hersmus, J. Trapman, and A. B. Houtsmuller Antiandrogens prevent stable DNA-binding of the androgen receptor J. Cell Sci., September 15, 2005; 118(18): 4187 - 4198. [Abstract] [Full Text] [PDF]

				K-M Rau, H-Y Kang, T-L Cha, S A Miller, and M-C Hung The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers Endocr. Relat. Cancer, September 1, 2005; 12(3): 511 - 532. [Abstract] [Full Text] [PDF]

				Z Culig, H Steiner, G Bartsch, and A Hobisch Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244. [Abstract] [Full Text] [PDF]

				C. E. Bohl, W. Gao, D. D. Miller, C. E. Bell, and J. T. Dalton Structural basis for antagonism and resistance of bicalutamide in prostate cancer PNAS, April 26, 2005; 102(17): 6201 - 6206. [Abstract] [Full Text] [PDF]

				H. C. Whitaker, S. Hanrahan, N. Totty, S. C. Gamble, J. Waxman, A. C. B. Cato, H. C. Hurst, and C. L. Bevan Androgen Receptor Is Targeted to Distinct Subcellular Compartments in Response to Different Therapeutic Antiandrogens Clin. Cancer Res., November 1, 2004; 10(21): 7392 - 7401. [Abstract] [Full Text] [PDF]

				D. Masiello, S.-Y. Chen, Y. Xu, M. C. Verhoeven, E. Choi, A. N. Hollenberg, and S. P. Balk Recruitment of {beta}-Catenin by Wild-Type or Mutant Androgen Receptors Correlates with Ligand-Stimulated Growth of Prostate Cancer Cells Mol. Endocrinol., October 1, 2004; 18(10): 2388 - 2401. [Abstract] [Full Text] [PDF]

				A. Biroccio and C. Leonetti Telomerase as a new target for the treatment of hormone-refractory prostate cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 407 - 421. [Abstract] [Full Text] [PDF]

				C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF]

				L. Wang, C.-L. Hsu, J. Ni, P.-H. Wang, S. Yeh, P. Keng, and C. Chang Human Checkpoint Protein hRad9 Functions as a Negative Coregulator To Repress Androgen Receptor Transactivation in Prostate Cancer Cells Mol. Cell. Biol., March 1, 2004; 24(5): 2202 - 2213. [Abstract] [Full Text] [PDF]

				M. J. Linja, K. P. Porkka, Z. Kang, K. J. Savinainen, O. A. Janne, T. L. J. Tammela, R. L. Vessella, J. J. Palvimo, and T. Visakorpi Expression of Androgen Receptor Coregulators in Prostate Cancer Clin. Cancer Res., February 1, 2004; 10(3): 1032 - 1040. [Abstract] [Full Text] [PDF]

				T. Hara, K. Nakamura, H. Araki, M. Kusaka, and M. Yamaoka Enhanced Androgen Receptor Signaling Correlates with the Androgen-refractory Growth in a Newly Established MDA PCa 2b-hr Human Prostate Cancer Cell Subline Cancer Res., September 1, 2003; 63(17): 5622 - 5628. [Abstract] [Full Text] [PDF]